Acceptance rate:
Time to first decision with review:
45 days*
Acceptance to publication:
27 days*
2023 total content views:
*median number of days

Aims and scope

BMJ Oncology is a new BMJ journal that aims to optimise cancer patient care and improve outcomes. An open access, online format supports the global reach and impact of BMJ Oncology content. The journal invites oncology experts to submit high-quality original research and review papers. Publishing consideration will be extended to papers that provide sound science across the broad spectrum of cancer research, investigation, treatment and practice. BMJ Oncology aims to improve cancer outcomes by:
  • Publishing a broad range of peer-reviewed articles that provide significant clinical, scientific and educational value
  • Reaching a wide international audience through BMJ’s global recognition and clinical following
  • Facilitating a close interaction between basic, translational and clinical sciences through publication and by fostering interdisciplinary research
  • Provoking scientific debate and discussion
  • Encouraging researchers, clinicians, patients and the public to engage with the journal content and contribute through social media and multimedia
For information about BMJ Oncology Editor-in-Chief Ananya Choudhury and the editorial team, please refer to the Editorial Board page.


BMJ Oncology is wholly owned by BMJ.

Journal information

Publication Model
Open access
Continuous online publication
Launch date
Digital Archives
Indexed by
Google Scholar
Peer Review Model
Single anonymised; the names of reviewers are hidden from the author
Online ISSN

Journal Statistics 2023

Speed Time to first decision without review: 2 days (median) Time to first decision with review: 45 days (median) Acceptance to publication: 27 days (median)
Reach 2023 total content views: 28516 2023 total Altmetric mentions: 7295

Contact information

For all contact information please refer to the contact us page.

For authors

Please refer to the Instructions for authors.


BMJ sales
Display advertising sales – worldwide except USA and Canada
Sophie Fitzsimmons (Sales Executive) sfitzsimmons@bmj.com
Online advertising sales – worldwide except USA and Canada
Marc Clifford (Sales Manager) mclifford@bmj.com
Display & online advertising sales – USA and Canada
Jim Cunningham jcunningham@cunnasso.com Tel: +1 201 767 4170
Information and rates on how to advertise in BMJ Oncology

Rights and permissions

Please refer to our Permissions guidelines


The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure. How we get these metrics
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
AllTrials logo
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.